lumasiran

Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial
BioSpace
Mon, 08/2/21 - 11:06 am
Alnylam
RNAi
renal decline
clinical trials
lumasiran
Alnylam makes case for lumasiran in infants ahead of FDA ruling
Fierce Biotech
Fri, 10/23/20 - 10:57 am
Alnylam
kidney disease
lumasiran
pediatric
FDA
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
BioSpace
Thu, 10/1/20 - 11:28 am
Alnylam
lumasiran
clinical trials
Primary Hyperoxaluria
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Fierce Biotech
Wed, 09/30/20 - 10:35 am
Alnylam
clinical trials
lumasiran
RNAi
PH1
Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data
Endpoints
Sun, 06/7/20 - 10:32 pm
Alnylam
clinical trials
RNAi
lumasiran
PH1
Alnylam nabs speedy review, setting up 3rd possible approval in 3 years
Endpoints
Tue, 05/26/20 - 11:12 am
Alnylam
RNAi
FDA
drug approvals
lumasiran
hyperoxaluria
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Pharmaceutical Business Review
Wed, 04/8/20 - 10:51 am
Alnylam
Primary Hyperoxaluria
FDA
lumasiran
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Tue, 12/17/19 - 10:29 am
Alnylam
lumasiran
clincial trials
RNAi
kidney disease
Primary Hyperoxaluria
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
EP Vantage
Sat, 10/19/19 - 01:36 pm
Novartis
fevipiprant
severe asthma
Alnylam
lumasiran
Primary Hyperoxaluria
Alnylam Pharmaceuticals Is "Launch Ready"
Motley Fool
Mon, 08/6/18 - 11:51 pm
Alnylam
FDA
Onpattro
TTRsc02
lumasiran
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
CP Wire
Thu, 05/3/18 - 11:34 am
Alnylam
lumasiran
Primary Hyperoxaluria
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
Thu, 05/3/18 - 11:12 am
Alnylam
lumasiran
Primary Hyperoxaluria